http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20020069140-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_863ce7924de9585e2fc7771a0aa9a15c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4703 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 |
| filingDate | 2002-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74ffb967ffc878b6c962f78866bb323b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82f963e39fe1c0714b6b28ec63a46579 |
| publicationDate | 2002-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20020069140-A |
| titleOfInvention | A Novel TRAF6 Inhibiting Protein |
| abstract | The present invention relates to novel isolated tumor necrosis factor receptor related factor 6 (TRAF6) inhibitory proteins or functional derivatives thereof. These proteins contain a KRAB domain at the N-terminus and 14 C 2 H 2 zinc finger motifs at the C-terminus, bind TRAF6 but not TRAF2 and TRAF3, and interact with TRAF6 to form tumor necrosis factor ( TNF) is a novel zinc finger protein characterized by inhibiting the activity of NF-κB or AP-1 in the signaling pathway. The present invention also relates to a nucleic acid sequence encoding the TRAF6 inhibitory protein or a functional derivative thereof, a recombinant plasmid comprising the nucleic acid sequence and a cell or cell line transfected or transformed with the recombinant plasmid. The present invention also relates to a method for producing a TRAF6 inhibitory protein or a functional derivative thereof using the transfectant or transformant. In addition, the present invention is characterized in that it comprises TRAF6 inhibitory protein expression plasmid, isolated TRAF6 inhibitory protein mRNA, isolated TRAF6 inhibitory protein, TRAF6 inhibitory protein antisense RNA or TRAF6 inhibitory protein as an active ingredient, TRAF6 or A pharmaceutical composition for the treatment or prophylaxis of diseases associated with the activity of NF-κB or AP-1. The present invention also relates to a pharmaceutical composition for the prevention or treatment of bone metabolic diseases, characterized in that it comprises a TRAF6 inhibitory protein expression plasmid, isolated TRAF6 inhibitory protein mRNA and / or isolated TRAF6 inhibitory protein as active ingredients. . |
| priorityDate | 2001-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 504.